previous chemotherapy for metastatic or locally recurrent breast cancer;

previous radiotherapy for metastatic breast cancer (except for metastatic bone pain relief);

other primary tumor within last 5 years, with the exception of basal or squamous skin cancer, or in situ cancer of the cervix;

clinically significant cardiovascular disease;

chronic daily treatment with aspirin (\>325mg/day) or clopidogrel (\>75mg/day).

A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2 Positive Metastatic Breast Cancer.